Publication Results (56)

• «
• 1
• 2
• »

• Metformin use and all-cause and prostate cancer–specific mortality among men with diabetes

  Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. J Clin Oncol. 2013; 31(25):3069-75. Epub 2013 Aug 5.

• Association between metformin use and risk of prostate cancer and its grade

  Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. J Natl Cancer Inst. 2013; 105(15):1123-31. Epub 2013 Jul 13.

• Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events

  Krahn MD, Bremner KE, Luo J, Alibhai SM. Curr Oncol. 2014; 21(3):e457-65.

• Changing patterns in competing causes of death in men with prostate cancer: a population based study

  Lu-Yao G, Stukel TA, Yao SL. J Urol. 2004; 171(6 Pt 1):2285-90.

• Vasectomy and risk of prostate cancer: population based matched cohort study

  Nayan M, Hamilton RJ, Macdonald EM, Li Q, Mamdani MM, Earle CC, Kulkarni GS, Jarvi KA, Juurlink DN. BMJ. 2016; 355:i5546.

• Orchidectomy and hormonal therapy of prostate cancer

  To T, Iscoe N, Klotz L, Naylor CD. Can J Urol. 1995; 2(1):109-15.

• Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut

  Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. BMJ. 2002; 325(7367):740.

• The effect of vasectomy reversal on prostate cancer risk: international meta-analysis of 684,660 men with vasectomies

  Randall S, Boyd J, Fuller E, Brooks C, Morris C, Earle CC, Ferrante A, Moorin R, Semmens J, Holman CDJ. J Urol. 2018; 200(1):121-5. Epub 2018 Mar 7.

• Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer

  Wallis CJ, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK. Br J Cancer. 2015; 112(6):977-82. Epub 2015 Feb 17.

• Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions

  Mercer SL, Goel V, Levy IG, Ashbury FD, Iverson DC, Iscoe NA. Can J Public Health. 1997; 88(5):327-32.

• Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer

  Young JW, Sutradhar R, Rangrej J, Marras C, Fleshner N, Alibhai SM. World J Urol. 2017; 35(9):1417-23. Epub 2017 Feb 15.

• Trends in hormonal management of prostate cancer: a population-based study in Ontario

  Bondy SJ, Iscoe NA, Rothwell DM, Gort EH, Fleshner NE, Paszat LF, Browman GP. Med Care. 2001; 39(4):384-96.

• Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men

  Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. J Urol. 2010; 184(3):918-23.

• Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis

  Wallis CJ, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA, Nam RK. Urology. 2015; 85(3):621-8.

• Androgen deprivation therapy for prostate cancer: prescribing behaviors and preferences among urologists

  Cheung DC, Martin LJ, Alibhai SMH, Komisarenko M, Dharma C, Niu Y, Warde P, Sridhar SS, Fleshner NE, Kulkarni GS, Finelli A. Can Urol Assoc J. 2022; May 20 [Epub ahead of print]. DOI: https://doi.org/10.5489/cuaj.7730

• The deleterious association between proton pump inhibitors and prostate cancer-specific mortality – a population-based cohort study

  Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M, Wallis CJD, Chandrasekar T, Klaassen Z, Saarela O, Penn L, Alibhai SMH, Fleshner N. Prostate Cancer Prostatic Dis. 2020; 23(4):622-9. Epub 2020 Jul 8. DOI: https://doi.org/10.1038/s41391-020-0248-9

• The suggested unique association between the various statin subgroups and prostate cancer

  Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M, Wallis CJD, Klaassen Z, Chandrasekar T, Ahmad AE, Sayyid RK, Saarela O, Penn L, Alibhai SMH, Fleshner N. Eur Urol Focus. 2021; 7(3):537-45. Epub 2020 Jun 30. DOI: https://doi.org/10.1016/j.euf.2020.06.005

• The suggested chemopreventive association of metformin with prostate cancer in diabetic patients

  Goldberg H, Mohsin FK, Berlin A, Chandrasekar T, Wallis CJD, Klaassen Z, Ahmad AE, Saskin R, Kenk M, Saarela O, Kulkarni GS, Alibhai SMH, Fleshner N. Urol Oncol. 2021; 39(3):191.e17-.e24. Epub 2020 Sep 17. DOI: https://doi.org/10.1016/j.urolonc.2020.08.032

• Long-term health care costs for prostate cancer patients on androgen deprivation therapy

  Krahn MD, Bremner KE, Luo J, Tomlinson G, Alibhai SMH. Curr Oncol. 2016; 23(5):e443-53. Epub 2016 Oct 26.

• June 2004

  • Use of anti-inflammatory drugs associated with greater risk of hospitalization for heart failure
  • Patients should see hospital physicians after discharge
  • Leading causes of global death and disability not being studied in clinical trials
  • Many common illnesses increase risk of suicide in elderly
  • Most deaths in men with prostate cancer not due to prostate cancer

• Management strategies and patient selection after a hospital funding reform for prostate cancer surgery in Canada

  Wettstein MS, Palmer KS, Kulkarni GS, Paterson JM, Ling V, Lapointe-Shaw L, Li AH, Brown A, Taljaard M, Ivers N. JAMA Netw Open. 2019; 2(8):e1910505. Epub 2019 Aug 30. DOI: 10.1001/jamanetworkopen.2019.10505.

• Population-based outcomes of men with a single negative prostate biopsy: importance of continued follow-up among older patients

  Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, Goldberg H, Perlis N, Madi R, Terris MK, Urbach DR, Fleshner NE. Urol Oncol. 2019; 37(5):298.e19-27. Epub 2019 Feb 13.

• Prostate-specific Antigen (PSA) Screening in Asymptomatic Men

  Slaughter P, Pinfold P, Laupacis A. March 2002

• Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study

  Nam RK, Cheung P, Herschorn A, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA. Oncology. 2014; 15(2):223-31. Epub 2014 Feb 1.

• Variation and trends in antidepressant prescription for men undergoing treatment for nonmetastatic prostate cancer: a population-based cohort study

  Matta R, Wallis CJD, Goldenberg MG, Hird AE, Klaassen Z, Kulkarni G, Kodama RT, Herchorn S, Nam RK. Eur Urol. 2018; 75(1):3-7. Epub 2018 Sep 18.

• September 2010

  • Forty percent of women in Ontario's urban areas not getting Pap tests
  • Several factors increase risk of fracture with androgen deprivation for prostate cancer
  • Radiodiagnostic tests during pregnancy result in low childhood cancer risk
  • Ontario seniors' use of ambulatory care varies by age, sex and socioeconomic status
  • Preoperative medical consultations associated with increased mortality and hospital stay

• January 2004

  • New approach needed for drug evaluation in Canada
  • Chest pain patients in higher SES neighbourhoods have shorter ambulance transport times
  • Elderly men in the U.S. are receiving excessive screening for prostate cancer
  • Heart failure index can help doctors predict risk of death
  • Dementia patients use more resources, but in a similar pattern to patients without dementia

• September 2013

  • Metformin may lower risk of prostate cancer death in men with diabetes
  • Fertility therapy not linked to subsequent risk of cardiovascular disease in women 
  • Flu carries higher risk for Guillain-Barré syndrome than flu shot 
  • Chinese and South Asians have 40% lower mortality risk after diabetes than Europeans
  • Cardiac patients given longer prescriptions at discharge more likely to continue medication

• Trends in prostate biopsy in Ontario, 1992-2014: a cohort study

  Lavallée LT, Breau RH, Fergusson D, van Walraven C. CMAJ Open. 2016; 4(4):E698-705.

• Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer

  Bunting PS, Goel V, Williams JI, Iscoe NA. CMAJ. 1999; 160(1):70-5.

• Effects of quality-based procedure hospital funding reform in Ontario, Canada: an interrupted time series study

  Li AH, Palmer KS, Taljaard M, Paterson JM, Brown A, Huang A, Marani H, Lapointe-Shaw L, Pincus D, Wettstein MS, Kulkarni GS, Wasserstein D, Ivers N. PLoS One. 15(8):e0236480. Epub 2020 Aug 19. DOI: https://doi.org/10.1371/journal.pone.0236480

• Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993–2000

  Simunovic M, Thériault ME, Paszat L, Coates A, Whelan T, Holowaty E, Levine M. Can J Surg. 2005; 48(2):137-42.

• Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy

  Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. J Urol. 2013; 189(1 Suppl):S12-8.

• Preventable diabetic complications after a cancer diagnosis in patients with diabetes: a population-based cohort study

  Worndl E, Fung K, Fischer HD, Austin PC, Krzyzanowska MK, Lipscombe LL. JNCI Cancer Spectr. 2018; 2(1):pky008. Epub 2018 May 11.

• Real-world practice patterns and predictors of continuous versus intermittent androgen deprivation therapy use for prostate cancer in older men

  Cheung DC, Alibhai SMH, Martin LJ, Komisarenko M, Dharma C, Warde P, Sridhar SS, Fleshner NE, Kulkarni GS, Finelli A. J Urol. 2021; 206(4):933-41. Epub 2021 May 25. DOI: https://doi.org/10.1097/JU.0000000000001876

• Validation of quality indicators for radical prostatectomy

  Chan EO, Groome PA, Siemens DR. Int J Cancer. 2008; 123(11):2651-7.

• Impact of androgen deprivation therapy on cardiovascular disease and diabetes

  Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF. J Clin Oncol. 2009; 27(21):3452-8. Epub 2009 Jun 8.

• The impact of the Choosing Wisely Campaign in urology

  Welk B, Winick-Ng J, McClure JA, Lorenzo AJ, Kulkarni G, Ordon M. Urology. 2018; 116:81-6. Epub 2018 Mar 20.

• Can we use administrative data to accurately identify patients who receive a prostate biopsy?

  Lavallée LT, Breau RH, Fergusson D, Walsh C, van Walraven C. JCO Clin Cancer Inform. 2018; (2):1-10. Epub 2018 Aug 31.

• Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study

  Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Hong NJL, Earle CC, Cheung M, Leighl NB, Coburn NG, DeAngelis C, Evans WK. CMAJ Open. 2020; 8(1):E191-8. Epub 2020 Mar 16. DOI: https://doi.org/10.9778/cmajo.20190114

• «
• 1
• 2
• »